Neurocrine Biosciences, Inc. (NBIX)
NASDAQ$110.75
Market Cap
$11.04B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
725 of 924
Rank in Industry
43 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
NBIX Insider Trading Activity
NBIX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $66,790,412 | 64 | 100 |
Related Transactions
| Norwalk Leslie V | director | 0 | $0 | 1 | $156,850 | $-156,850 |
| Sharp Shalini | director | 0 | $0 | 1 | $156,943 | $-156,943 |
| POPS RICHARD F | director | 0 | $0 | 1 | $297,860 | $-297,860 |
| ROBERTS EIRY | Chief Medical Officer | 0 | $0 | 4 | $596,753 | $-596,753 |
| Onyia Jude | Chief Scientific Officer | 0 | $0 | 3 | $649,885 | $-649,885 |
| Boyer David W. | Chief Corp. Affairs Officer | 0 | $0 | 5 | $1.03M | $-1.03M |
| Lippoldt Darin | Chief Legal Officer | 0 | $0 | 5 | $2.07M | $-2.07M |
| RASTETTER WILLIAM H | director | 0 | $0 | 1 | $2.09M | $-2.09M |
| Delaet Ingrid | Chief Regulatory Officer | 0 | $0 | 13 | $2.93M | $-2.93M |
| LYONS GARY A | director | 0 | $0 | 3 | $3.58M | $-3.58M |
| Cooke Julie | Chief Human Resources Officer | 0 | $0 | 6 | $4M | $-4M |
| MORROW GEORGE J | director | 0 | $0 | 1 | $5.58M | $-5.58M |
| SHERWIN STEPHEN A | director | 0 | $0 | 2 | $6.95M | $-6.95M |
| ABERNETHY MATT | Chief Financial Officer | 0 | $0 | 7 | $7M | $-7M |
| Gano Kyle | Chief Executive Officer | 0 | $0 | 4 | $9.85M | $-9.85M |
| BENEVICH ERIC | Chief Commercial Officer | 0 | $0 | 5 | $11.92M | $-11.92M |
| GORMAN KEVIN CHARLES | director | 0 | $0 | 4 | $23.2M | $-23.2M |
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA …
Insider Activity of Neurocrine Biosciences, Inc.
Over the last 12 months, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $66.79M worth of Neurocrine Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $57.79M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 59,000 shares for transaction amount of $351,345 was made by BVF PARTNERS L P/IL (10 percent owner) on 2011‑10‑12.
List of Insider Buy and Sell Transactions, Neurocrine Biosciences, Inc.
| 2025-02-14 | Sale | ROBERTS EIRY | Chief Medical Officer | 500 0.0005% | $115.04 | $57,521 | -0.85% | |
| 2025-02-13 | Sale | GORMAN KEVIN CHARLES | director | 5,844 0.0057% | $116.69 | $681,914 | -2.27% | |
| 2025-02-13 | Sale | Gano Kyle | Chief Executive Officer | 2,558 0.0025% | $116.85 | $298,908 | -2.27% | |
| 2025-02-13 | Sale | BENEVICH ERIC | Chief Commercial Officer | 2,154 0.0021% | $116.73 | $251,428 | -2.27% | |
| 2025-02-13 | Sale | Lippoldt Darin | Chief Legal Officer | 2,184 0.0021% | $116.75 | $254,992 | -2.27% | |
| 2025-02-13 | Sale | ABERNETHY MATT | Chief Financial Officer | 2,558 0.0025% | $116.86 | $298,923 | -2.27% | |
| 2025-02-13 | Sale | ROBERTS EIRY | Chief Medical Officer | 1,718 0.0017% | $116.85 | $200,742 | -2.27% | |
| 2025-02-13 | Sale | Cooke Julie | Chief Human Resources Officer | 1,551 0.0015% | $116.78 | $181,129 | -2.27% | |
| 2025-02-13 | Sale | Onyia Jude | Chief Scientific Officer | 2,879 0.0028% | $116.79 | $336,239 | -2.27% | |
| 2025-02-13 | Sale | SHERWIN STEPHEN A | director | 13,831 0.0136% | $116.69 | $1.61M | -2.27% | |
| 2025-02-13 | Sale | Delaet Ingrid | Chief Regulatory Officer | 1,471 0.0014% | $116.71 | $171,674 | -2.27% | |
| 2025-02-13 | Sale | Boyer David W. | Chief Corp. Affairs Officer | 1,785 0.0018% | $116.74 | $208,387 | -2.27% | |
| 2025-02-10 | Sale | GORMAN KEVIN CHARLES | director | 2,274 0.0022% | $118.37 | $269,167 | -3.72% | |
| 2025-02-10 | Sale | Gano Kyle | Chief Executive Officer | 980 0.0009% | $118.39 | $116,020 | -3.72% | |
| 2025-02-10 | Sale | BENEVICH ERIC | Chief Commercial Officer | 980 0.0009% | $118.31 | $115,940 | -3.72% | |
| 2025-02-10 | Sale | Lippoldt Darin | Chief Legal Officer | 911 0.0009% | $118.25 | $107,727 | -3.72% | |
| 2025-02-10 | Sale | ABERNETHY MATT | Chief Financial Officer | 980 0.0009% | $118.27 | $115,909 | -3.72% | |
| 2025-02-10 | Sale | ROBERTS EIRY | Chief Medical Officer | 980 0.0009% | $118.22 | $115,853 | -3.72% | |
| 2025-02-10 | Sale | Cooke Julie | Chief Human Resources Officer | 700 0.0007% | $118.28 | $82,793 | -3.72% | |
| 2025-02-10 | Sale | Boyer David W. | Chief Corp. Affairs Officer | 700 0.0007% | $118.31 | $82,820 | -3.72% |
Total: 788
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| BVF PARTNERS L P/IL | 10 percent owner | 3527700 3.5382% | $390.69M | 36 | 10 | <0.0001% |
| MITCHELL W THOMAS | director | 1000 0.001% | $110,750.00 | 2 | 7 | +29.05% |
Historical Insider Profitability vs. Competitors
$910,099,463 | 123 | 11.52% | $2.63B | |
$23,522,750 | 59 | -6.74% | $5.16B | |
$14,599,168 | 59 | 12.79% | $1.36B | |
$86,177,559 | 48 | 44.65% | $13.96B | |
$97,642,477 | 41 | -10.58% | $839.35M |
NBIX Institutional Investors: Active Positions
| Increased Positions | 330 | +51.81% | 12M | +13.34% |
| Decreased Positions | 285 | -44.74% | 10M | -11.04% |
| New Positions | 112 | New | 3M | New |
| Sold Out Positions | 74 | Sold Out | 2M | Sold Out |
| Total Postitions | 682 | +7.06% | 95M | +2.3% |
NBIX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Blackrock, Inc. | $1.76M | 14.78% | 14.78M | +526,674 | +3.69% | 2024-12-31 |
| Vanguard Group Inc | $1.2M | 10.12% | 10.12M | +122,681 | +1.23% | 2024-12-31 |
| State Street Corp | $580,676.00 | 4.89% | 4.89M | -257,156 | -5% | 2024-12-31 |
| Dodge & Cox | $358,110.00 | 3.02% | 3.02M | +2M | +134.23% | 2024-12-31 |
| Citadel Advisors Llc | $301,324.00 | 2.54% | 2.54M | +773,519 | +43.84% | 2024-12-31 |
| Renaissance Technologies Llc | $295,541.00 | 2.49% | 2.49M | -85,149 | -3.31% | 2024-12-31 |
| Aqr Capital Management Llc | $225,199.00 | 1.9% | 1.9M | +53,610 | +2.91% | 2024-12-31 |
| Geode Capital Management, Llc | $222,607.00 | 1.88% | 1.88M | +15,830 | +0.85% | 2024-12-31 |
| Bellevue Group Ag | $216,070.00 | 1.82% | 1.82M | -43,800 | -2.35% | 2024-12-31 |
| Morgan Stanley | $186,782.00 | 1.57% | 1.57M | +223,916 | +16.59% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.